Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
641 to 660 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Rare germline variants in pancreatic cancer and multiple primary cancers: an autopsy study. | Eur J Cancer Prev | 2023 | 36896836 | PubTator, text mining | PubMed |
| Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer. | Front Genet | 2023 | 36896237 | PubTator, text mining | PubMed |
| Prognostic value of genomic mutations in metastatic prostate cancer. | Heliyon | 2023 | 36895385 | PubTator, text mining | PubMed |
| Are population level familial risks and germline genetics meeting each other? | Hered Cancer Clin Pract | 2023 | 36882784 | PubTator, text mining | PubMed |
| SIRT1 activation synergizes with FXR agonism in hepatoprotection via governing nucleocytoplasmic shuttling and degradation of FXR. | Acta Pharm Sin B | 2023 | 36873184 | PubTator, text mining | PubMed |
| Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception. | Breast Cancer Res Treat | 2023 | 36856935 | PubTator, text mining | PubMed |
| Prevalence of Pathogenic Germline Mutations in 13 Hereditary Cancer-Related Genes in Breast Cancer Patients in Narathiwat Province, Thailand. | Asian Pac J Cancer Prev | 2023 | 36853301 | PubTator, text mining | PubMed |
| L-Ascorbic Acid 2-Phosphate Attenuates Methylmercury-Induced Apoptosis by Inhibiting Reactive Oxygen Species Accumulation and DNA Damage in Human SH-SY5Y Cells. | Toxics | 2023 | 36851019 | PubTator, text mining | PubMed |
| Evaluation of genetic alterations in hereditary cancer susceptibility genes in the Ashkenazi Jewish women community of Mexico. | Front Genet | 2023 | 36845387 | PubTator, text mining | PubMed |
| Genetic and epigenetic instability induced by betel quid associated chemicals. | Toxicol Rep | 2023 | 36845258 | PubTator, text mining | PubMed |
| Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches. | J Pers Med | 2023 | 36836518 | PubTator, text mining | PubMed |
| New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. | Int J Mol Sci | 2023 | 36835456 | PubTator, text mining | PubMed |
| Association of FANCM Mutations with Familial and Early-Onset Breast Cancer Risk in a South American Population. | Int J Mol Sci | 2023 | 36835452 | PubTator, text mining | PubMed |
| Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy. | Int J Mol Sci | 2023 | 36834660 | PubTator, text mining | PubMed |
| Unexpected Findings in Hereditary Breast and Ovarian Cancer Syndrome: Low-Level Constitutional Mosaicism in BRCA2. | Genes (Basel) | 2023 | 36833429 | PubTator, text mining | PubMed |
| Hereditary Cancer Syndrome in a Family with Double Mutation in BRIP1 and MUTYH Genes. | Genes (Basel) | 2023 | 36833355 | PubTator, text mining | PubMed |
| Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. | Genes (Basel) | 2023 | 36833203 | PubTator, text mining | PubMed |
| Functional Analyses of Rare Germline Missense BRCA1 Variants Located within and outside Protein Domains with Known Functions. | Genes (Basel) | 2023 | 36833189 | PubTator, text mining | PubMed |
| Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. | Cancers (Basel) | 2023 | 36831640 | PubTator, text mining | PubMed |
| The impact of coding germline variants on contralateral breast cancer risk and survival. | Am J Hum Genet | 2023 | 36827971 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=33